Author

P. A. Clemons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Organism:human· 4 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Approach:statistical model· 2

Frequent Co-Authors

S. L. Schreiber· 6 shared B. K. Hua· 2 shared C. W. Coley· 2 shared D. E. Root· 2 shared F. Berst· 2 shared F. J. Zecri· 2 shared J. W. Mason· 2 shared K. Briner· 2 shared

Activity by Year

2018-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersBiochemistry

S. L. Schreiber

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Diversity-oriented synthesis encoded by deoxyoligonucleotides

L. Hudson, J. W. Mason, M. V. Westphal, M. J. R. Richter, J. R. Thielman, B. K. Hua, C. J. Gerry, G. Xia, H. L. Osswald, J. M. Knapp, Z. Y. Tan, P. Kokkonda, B. I. C. Tresco, S. Liu, A. G. Reidenbach, , K. Briner

The paper describes the design, synthesis, and validation of a 3.7 million-member DNA-encoded library using diversity-oriented synthesis to enhance structural diversity for drug discovery.

bioRxiv · Oct 16, 2022Biochemistry

DNA-encoded library (DEL)-enabled discovery of proximity-inducing small molecules

J. W. Mason, L. Hudson, M. V. Westphal, A. Tutter, G. Michaud, W. Shu, X. Ma, C. W. Coley, P. A. Clemons, S. Bonazzi, F. Berst, F. J. Zecri, K. Briner, S. L. Schreiber

This paper uses DNA-encoded libraries to discover small molecules that induce protein-protein associations between BRD4 and VHL-elongin C-elongin B.

bioRxiv · Oct 13, 2022Pharmacology & Toxicology

Mapping the landscape of genetic dependencies in chordoma

T. Sharifnia, M. J. Wawer, A. Goodale, Y. Lee, M. Kazachkova, J. M. Dempster, S. Muller, J. Levy, D. M. Freed, J. Sommer, J. Kalfon, F. Vazquez, W. C. Hahn, D. E. Root, P. A. Clemons, S. L. Schreiber

This study identifies essential genes in chordoma using CRISPR screens, revealing new therapeutic targets like PTPN11 and confirming known dependencies such as TBXT.

bioRxiv · Aug 17, 2022Cancer Biology

Reference compounds for characterizing cellular injury in high-content cellular morphology assays

J. L. Dahlin, B. K. Hua, B. E. Zucconi, S. D. Nelson, S. Singh, A. E. Carpenter, J. H. Shrimp, E. Lima-Fernandes, M. J. Wawer, L. P. Chung, A. Agrawal, M. O'Reilly, D. Barsyte-Lovejoy, M. Szewczyk, F. Li, , B. K. Wagner

The paper profiles 218 cytotoxic and nuisance compounds in U-2 OS cells to create reference compounds for improving assay optimization and compound prioritization in cellular morphology assays.

bioRxiv · Jul 12, 2022 · PreprintPharmacology & Toxicology

Optimized chemogenomic library design strategies for precision oncology

P. Athanasiadis, B. Ravikumar, N. O. Carragher, P. A. Clemons, T. Johanssen, D. Ebner, T. Aittokallio

The paper presents strategies for designing optimized chemogenomic libraries for precision oncology, focusing on cancer-related targets and biological pathways.

bioRxiv · Nov 30, 2020Cancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology

Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors

J. K. Eaton, L. Furst, R. A. Ruberto, D. Moosmayer, R. C. Hillig, A. Hilpmann, K. Zimmermann, M. J. Ryan, M. Niehues, V. Badock, A. Kramm, S. Chen, P. A. Clemons, S. Gradl, C. Montagnon, , S. L. Schreiber

This paper identifies nitrile oxide electrophiles as a new class of GPX4 inhibitors that overcome limitations of existing chloroacetamide-based inhibitors.

bioRxiv · Sep 5, 2018Biochemistry